Helus Psychedelic Depression Drug Wins Pivotal Phase 3

Depression is a word people use loosely, but in medicine it describes something far more serious than a bad week. Major depressive disorder involves a low mood or a loss of interest in daily life that lasts most of the day, nearly every day, for at least two weeks. It often brings poor sleep, changes in appetite, trouble concentrating, feelings of guilt or low self-worth and, in some cases, thoughts of suicide. It can strain relationships and make it hard to keep up at school or work. 

The World Health Organization estimates that about 332 million people worldwide live with depression, including 5.7% of adults. In the U.S., the National Institute of Mental Health reports that roughly 21 million adults, or 8.3%, had at least one major depressive episode in a single year. Even in high-income countries, only about one third of people with depression receive mental health treatment. 

Generalized anxiety disorder is a close relative. People who have it feel excessive, hard to control worry about ordinary things such as work, health or money, on more days than not for at least six months. The worry usually comes with physical tension, and it can get in the way of work, relationships and daily routines. Many people live with both conditions at once, which is why researchers often study them side by side. 

Anxiety disorders as a group are the most common mental disorders in the world, affecting an estimated 359 million people in 2021, or about 4.4% of the global population. Only about one in four of those people receive treatment. In the U.S., about 2.7% of adults have generalized anxiety disorder in a given year, and 5.7% will experience it at some point in their lives. 

The standard medicines for both conditions, mainly daily antidepressants, help many people, but they can take weeks to work and often leave symptoms behind. A new generation of serotonin-targeting drugs, some derived from psychedelic compounds, aims to close that gap.

That context makes today’s news from Helus Pharma Inc. (NASDAQ: HELP) worth a closer look. The Toronto company reported that its lead drug, HLP003, met its main goal in a late-stage trial called APPROACH. HLP003 is a deuterated form of psilocin, the compound the body produces when it breaks down psilocybin. Deuteration, a small chemical change, is meant to make the drug more stable and consistent. 

The study enrolled 222 adults with moderate to severe depression who stayed on their existing antidepressants. Patients received two doses of HLP003 (16 mg) or placebo, three weeks apart. Researchers tracked symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS), a clinician-rated scale where a lower score means fewer symptoms. 

At six weeks, the main measurement point, scores on HLP003 fell by 19.5 points, compared with 11.9 points on placebo. That is a difference of −7.6 points (p<0.0001), with an effect size of 0.653. By Day 2, the gap was already −5.0 points (p=0.0013), and at Week 12 it held at −7.0 points (p<0.0001). Response and remission rates beat placebo at every reported time point. The drug was generally well tolerated, with mostly mild to moderate side effects, although there were three treatment-related serious adverse events. 

APPROACH is the first of three studies in the PARADIGM Phase 3 program. A second pivotal trial, EMBRACE, is expected to report results in the fourth quarter of 2027, and a long-term study called EXTEND is examining safety, durability and redosing. HLP003 already holds the FDA’s Breakthrough Therapy designation, and management has pointed to 2028 for a New Drug Application, the formal request for U.S. approval. 

A sister compound, HLP004, is being developed for generalized anxiety disorder. In a small Phase 2 study earlier this year, it produced roughly a 10-point improvement on a standard anxiety scale when added to existing treatment. 

A clean Phase 3 result is a big moment for a company of this size, and it may draw attention to the wider psychedelic medicine field. The market’s first reaction was cooler, with shares falling about 21% early in the session. The questions now are whether EMBRACE repeats these numbers and how the company pays for the road to approval. 

Related posts

Subscribe to Newsletter

Subscribe VBNG Newsletter for news. Let's stay updated!